Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2024 Jun 6;18(6):e0011877. doi: 10.1371/journal.pntd.0011877

An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection

Jonathan L M Fontes 1,2, Ricardo Khouri 1, Luis Gustavo C Reinaldo 3, Erina M A Hassegawa 1, Antônio José Meneses Filho 4, Caroline V B de Melo 1,2, Pablo Ivan P Ramos 1, Rafael de Deus Moura 5, Carla Pagliari 6, Marta Santos 1, Raimundo José C Araújo Jr 5, Johan Van Weyenbergh 7, Luiz A R de Freitas 1, Carlos Henrique N Costa 4, Washington L C dos-Santos 1,2,*
Editor: Abhay R Satoskar8
PMCID: PMC11265696  PMID: 38843306

Abstract

The spleen plays a pivotal role in the pathogenesis of visceral leishmaniasis. In severe forms of the disease, the spleen undergoes changes that can compromise its function in surveilling blood-circulating pathogens. In this study, we present an integrated analysis of the structural and gene expression alterations in the spleens of three patients with relapsing visceral leishmaniasis, two of whom were coinfected with HIV. Our findings reveal that the IL6 signaling pathway plays a significant role in the disorganization of the white pulp, while BCL10 and ICOSLG are associated with spleen organization. Patients coinfected with HIV and visceral leishmaniasis exhibited lower splenic CD4+ cell density and reduced expression of genes such as IL15. These effects may contribute to a compromised immune response against L. infantum in coinfected individuals, further impacting the structural organization of the spleen.

Author summary

While most individuals recover after contracting visceral leishmaniasis, there are cases where patients experience a relapsing form of the disease. This response pattern to Leishmania infection is linked to alterations in spleen structure. Until now, these spleen changes had only been examined in dogs and laboratory animals. In our study, we provide data on the disorganization of spleen structure in three patients diagnosed with VL, two of whom were also co-infected with HIV. The observed patterns of spleen disorganization closely resembled those seen in dogs. Our study emphasizes the involvement of IL6, BCL10, and ICOSLG in this process.

Introduction

Zoonotic visceral leishmaniasis (VL), caused by Leishmania infantum, is endemic in Brazil, various parts of the American Continent, and the Mediterranean Basin. The disease manifests through clinical symptoms such as fever, emaciation, hepatosplenomegaly, paleness, pancytopenia, bleeding diathesis, and a weakened immune response to bacterial infections [1,2]. While most patients respond to treatment with pentavalent antimony (SbV) or amphotericin B, there exists a subset with a poor response to conventional therapy, leading to a relapsing form of the disease [3,4]. Understanding the factors contributing to the progression of VL remains limited, yet HIV co-infection and other immunosuppressive conditions have been linked to a poorer prognosis [5].

The spleen, a significant secondary lymphoid organ, plays a vital role in immune surveillance against blood-circulating pathogens [6,7]. In severe VL cases, the spleen is consistently affected and is thought to underlie key clinical manifestations and disease progression [8,9]. Hypersplenism observed in VL contributes to anemia and may be associated with bleeding tendencies [1013]. Furthermore, disruption of spleen white pulp (WP) and replacement of cell populations may transform the spleen into a permissive environment for parasite survival and proliferation [9,1416].

This study investigates the association between clinical presentation, spleen histology, and gene expression in three patients exhibiting relapsing forms of VL unresponsive to conventional therapy with SbV or amphotericin B. These patients underwent splenectomy as an adjunctive therapeutic measure. The descriptive approach was expanded by comparing the gene expression profiles with those of health patients from publicly available data. The information presented herein aim to contribute to our understanding of the pathways involved in susceptibility to an inadequate response to L. infantum infection.

Results

Clinical and laboratory data

Clinical parameters are summarized in Table 1. Infection was confirmed in all patients by the identification of amastigotes in bone marrow aspirates. Each of the three patients had experienced at least one year of visceral leishmaniasis (VL) with a minimum of four relapses, despite undergoing conventional treatment. Patients VL1 and VL3 had been living with HIV infection for nine and seven years, respectively. All patients presented with a palpable spleen below the left costal edge: VL1 (18cm), VL2 (12cm), and VL3 (4cm). Additional clinical information can be found elsewhere [17].

Table 1. Clinical parameters of VL patients splenectomized due to relapses after conventional treatment failure.

PATIENT
PARAMETERS VL1 VL2 VL3
Age 33 55 45
Sex M M F
Disease duration
Years living with HIV
9 - 7
Years with VL 5 1 3
Relapses 5 5 4
Splenectomy (year) 2015 2015 2015
Pre-splenectomy parameters:
Bone marrow amastigotes + + +
HIV copies <50 - Undetectable
Hemoglobin (g/dL) 6.6 8.7 9.0
White blood cell count /mm3 1170 1090 1420
CD4 count/mm3 33 - 104
Platelets/ml (103) 115 155 90
Post-splenectomy parameters:
Bone marrow amastigotes
ND ND +
Hemoglobin (g/dL) 7.8 14.5 10.1
White blood cell counts 4840 5800 5200
CD4 count/mm3 135 - 436
Platelets/ml (103) 194 383 101
Additional VL control treatment - - Intranasal SbV
Outcome Death at the 244th day post-splenectomy Clinical cure Death at 742nd day post-splenectomy

ND–Not done

Before splenectomy, all patients experienced anemia and leukopenia. Patients VL1 and VL3 also presented with thrombocytopenia (platelet count less than 150,000/μL). Post-splenectomy, a mild improvement in hemoglobin levels was observed in all patients; however, VL1 and VL3 continued to exhibit signs of anemia. There was an improvement in the blood leukocyte counts for all patients. Additionally, the TCD4+ count increased in patients VL1 and VL3 after splenectomy. Unfortunately, two patients died, as previously described [17]: VL1 due to respiratory distress 244 days post-splenectomy, and VL3 due to severe digestive bleeding 742 days after the splenectomy procedure.

Histological analysis

The findings from spleen histological analysis are summarized in Table 2. Patient VL3 exhibited a well-organized spleen (type 1) with a hyperplastic WP. Patient VL2 displayed a type 1 spleen with slightly organized WP and mildly atrophic lymphoid follicles. Patient VL1, however, presented with a type 3 spleen—disorganized and with atrophic lymphoid WP, featuring small follicles and a marginal zone (Fig 1). Remarkably, in this patient, the WP comprised only 5% of the total splenic tissue area. Plasmacytosis was either moderate or intense in the red pulp (RP) of all patients, slight in the periarteriolar lymphoid sheath (PALS) of patient VL3, and moderate in patients VL1 and VL2. Notably, infected macrophages were observed in all spleen compartments, consistently displaying high amastigote density.

Table 2. Histological analysis of spleen from VL patients.

PARAMETER PATIENTS
VL1 VL2 VL3
Spleen size below left costal edge (cm) 18 12 4
Spleen weight (g) 1882 1066 742
White pulp:
    Size (%)
5.0 10.0 21.7
    Organization (type) 3 1 1
Lymphoid follicle1:
    Size
-2.5 -0.7 2.0
    Germinal center size -2.0 -0.7 3.0
    Infected macrophage 1.3 0.3 3.0
    Hyaline deposits 1.0 1.0 0.0
Marginal and peri-follicular zone1:
    Size
-2.3 -0.3 0.0
    Infected macrophages 1.5 0.0 2.0
    Granuloma 1.0 0.0 2.0
    Plasma cells 1.0 0.0 0.0
PALS1:
    Size
-0.5 0.3 0.0
    Infected macrophages 1.8 2.0 1.3
    Plasma cells 2.3 2.3 1.0
Red pulp1:
    Cell density
-0.8 0.0 0.0
    Lymphocytes 1.3 1.0 1.0
    Macrophages 3.0 3.0 3.0
    Infected macrophages 3.0 2.7 3.0
    Infection density 3.0 3.0 3.0
    Granuloma 0.5 0.0 1.3
    Plasma cells 2.0 2.0 3.0
    Russel bodies/Mott cells 1.3 1.7 1.0
    Neutrophils 0.5 1.0 0.0
    Mast cells 0.0 0.0 0.3
Extramedullary hematopoiesis:
    Erythroblasts
0.8 0.0 0.3
    Megakaryocytes 0.8 0.7 0.0
    Sinus size 2.3 2.0 1.0
    Iron deposits 0.3 0.3 0.0

1 semiquantitative scores

Fig 1. Histological and leukocyte distribution in spleen from patients with VL.

Fig 1

Patient VL1 presents a spleen type 3, with atrophy of lymphoid follicles. Patient VL2 presents a spleen type 1, with slight organized lymphoid follicle. Patient VL3 presents a well-structured WP and well-defined sub compartments, classified as spleen type 1.

Leukocyte phenotype and cytokine-producing cells

All cell quantification data following immunohistochemistry labeling are presented in Table 3. Notably, a noteworthy observation is the decreased density observed across some leukocytes population, including cytokines, FoxP3, and caspase 3-expressing cells, both in the WP and the RP of patient VL1, whose spleen was disorganized. Surprisingly, only the percentage of CD3, CD4, CD8, CD68, and counts of IL6-positive cells were either similar or higher compared to those observed in patients with organized spleens.

Table 3. Cell distribution in spleen compartments.

Parameters VL1 VL2 VL3
White Pulp
CD3 (%) 31 27 11
CD4 (%) 16 20 7
CD8 (%) 33 10 11
CD20 (%) 28 60 34
CD79α (%) 30 57 43
CD68 (cell/mm2) 547 151 173
IL1β (cell/mm2) 15 10 0
IL4 (cell/mm2) 0 4 8
IL6 (cell/mm2) 37 10 15
IL10 (cell/mm2) 0 4 3
IL17 (cell/mm2) 44 85 60
TNFα (cell/mm2) 18 92 47
TGFβ (cell/mm2) 0 19 0
IFNγ (cell/mm2) 0 3 13
Caspase 3 (cell/mm2) 8 19 140
Foxp3 (cell/mm2) 19 136 198
Red Pulp
CD3 (%) 21 12 13
CD4 (%) 4 2 4
CD8 (cell/mm2) 2264 547 1586
CD20 (cell/mm2) 593 683 896
CD68 (cell/mm2) 1154 861 898
CD79α (cell/mm2) 767 1896 1682
IL1β (cell/mm2) 1 6 1
IL4 (cell/mm2) 0 0 8
IL6 (cell/mm2) 47 37 42
IL10 (cell/mm2) 0 0 10
IL17 (cell/mm2) 23 55 294
TGFβ (cell/mm2) 0 5 0
IFNγ (cell/mm2) 0 2 34
TNFα (cell/mm2) 121 324 101
Caspase 3 (cell/mm2) 8 17 18
Foxp3 (cell/mm2) 1 885 511

Values of leukocytes and cytokines stained by immunohistochemistry. For some leukocytes were used percentual of area stained per white pulp or red pulp. These values represent the mean of 5 different areas per case.

Furthermore, it’s worth noting that the density of B cells, IL-17, and TNF-producing cells was higher, while CD68+ macrophages appear to be lower in the patient without HIV infection compared to those in patients with HIV infection.

Gene expression in VL patients

In this study, spleens from three patients with severe visceral leishmaniasis underwent evaluation for the expression of 590 genes using the nCounter platform. We incorporated the spleen transcriptome data from three normal donors obtained from publicly available sources (GTEx project) to serve as a control group. Our findings reveal distinct expression patterns of these genes between VL patients (n = 3) and the control group (n = 3), as depicted in the heatmap shown in Fig 2A. Additionally, through an unsupervised analysis using principal component analysis (PCA), we observed a notable disparity in gene signatures between patients with VL and spleen type 1 (VL3 and VL2) compared to the patient with spleen type 3 (VL1), as illustrated in Fig 2B.

Fig 2. Gene expression analysis of spleen from patients with VL.

Fig 2

A) Heatmap demonstrate that gene signature differs from patients with VL to normal donors and each band correspond to a different gene. Scale bar represents Log2 of Fold Change. Data were organized based on the gene expression of VL1 from the most expressed to the last expressed. B) Using an unsupervised analysis, we demonstrate that gene profile differs among VL patients, clustering organized spleen (patients VL2 and VL3) separated from disorganized spleen (patient VL1). Each dot represents the PCA value of each patient based on PCA analysis. Blue dot–Normal donor; Yellow dot–VL patient. C) IL6 signaling pathway adapted from Kandasamy and colleagues (2010) [18]. This pathway represents the signaling mechanism of IL6 in humans, genes upregulated in the spleen of patients with VL found on our analysis are highlighted in red, other genes presented at this graphic did not present expression change statistically significant or were not analyzed in our data set.

We identified 168 differentially expressed genes (DEGs) and most of these genes play pivotal roles in B cell proliferation and germinal center formation. Upregulated genes like BCL10 and ICOSLG were notably prominent in VL2 and VL3 patients, while genes such as CCR7 and RIPK1, associated respectively with T cell migration and apoptosis induction, exhibited downregulation, particularly in VL1 and VL3 patients (S3 Table).

Our analysis of Canonical Pathways revealed an upregulation of genes involved in signaling through IL6 in VL patients, particularly evident in VL1 patient, including genes such as JAK1, JAK2, and PRDM1 (Fig 2C).

Integrative analysis

Aiming to identify differences between parameters in patient with VL only (patient VL2) or VL with HIV coinfected (patients VL1 and VL3), we performed a supervised analysis. Data were normalized and clusterized by Pearson correlation. The of number of counts per genes, laboratory parameters, and cell counting in IHC presented in S2 Fig.

This analysis revealed group of parameters more associated to each patient: To the patient VL2 without HIV coinfection and organized spleen the cluster with genes as CXCL9, IL15, SOD2, IL32, GBP1, IRAK2, RIPK1, S100A9, IL6ST, CD45_PTPRC, the cells CD20+ and TGFβ+ in WP, cytokines IFNγ, TNFα, and IL1β in RP.

Among patients coinfected with both VL and HIV, we identified two distinct spleen types. Notably, the organized spleen type and VL-HIV coinfected was associated to genes as AHR, BID, C1QA, CCL8, CCRL2, CLEC4A, CMKLR1, CSF3R, EIF2AK2, ICOSLG, ILF3, LAMP3, MRC1, PSMD7, SMS and SRC; cells CASP3+, IL4+ and IFNγ+in the WP, and the cells IL4+, IL10+, IL17+, TGFβ+, CD20+ in the RP. Distinctly, VL1 patient, that has disorganized spleen and VL-HIV coinfection was related to SOD1, STAT3, STAT4, ICOS, TRAF6 and IRF3 genes, and CD8+ cells in the RP and expression of IL6 in both regions of spleen.

Discussion

In this study we took the advantage of accessing an unusual specimen of spleens removed from patients with a severe form of VL, unresponsive to conventional therapeutics. The availability of these specimens allowed to confirm that human VL evolves with stages of splenic lymphoid hyperplasia and atrophy and may evolve to WP disruption and changes in leukocyte populations in the spleen compartments. These changes have already been observed in dogs naturally infected with L. infantum and in hamsters with experimental VL [15,19]. Although this small case series is not suitable for definitive conclusions, it highlights aspects that are supported by previous experimental observations, deserving to be explored in future studies using a larger series. For instance, as shown in the study by Silva and colleagues (2012) [20], in dogs with severe VL atrophic changes and WP disruption were intense in the lymphoid follicles and marginal zones and was almost unperceived in PALS. Similar predominance of changes in the lymphoid follicle was observed in the patient VL1 (with type 3 spleen).

Also, in agreement with the studies performed in dogs, herein we show a decrease in the number of B lymphocytes in the WP compartments and an increase of plasma cells in the RP. The reason of why plasma cell persists even after WP disruption is still not completely elucidated. In dogs with VL and disorganized spleen there is up-regulation of BAFF, APRIL and CXCL12, factors associated with extended survival and homing of plasma cells [21,22]. However, in this study we were not able to find differences in BAFF and APRIL expression, between the normal reference spleens and the spleens of infected patients. Furthermore, some of these plasma cells may accumulate in the RP following an extrafollicular differentiation pathway [23].

The gene expression pattern seen in the spleen of patients with VL was different from that observed in the normal spleens used as reference. Despite of analysis of bulk RNA spleen samples did not allow to understand how genes are being expressed at cellular level, in this work we observed that the pattern of DEGs in VL are related to inflammatory response, cellular and blood cell homeostasis and signaling by the B cell activator factor and IL6 cytokine. These pathways inflammation process and cell cycle process are highly expressed in blood and spleen of hamsters with experimental visceral leishmaniasis [24,25].

Among the investigated genes and cellular characterization by IHC, we found that IFNG gene appeared highly expressed in VL patients, as observed in other transcriptional studies in human and experimental VL [2426], and the gene expression pattern in VL3 patient parallels to the number of IFNγ + cells present in the spleen. However, only a few cells stained for IFNγ+ were observed in the IHC staining of the spleen of the patients in this and in a previous study [27]. It is still not clear the difference between gene expression and IHC finding. The fact that all these patients presented treatment failure and relapses of disease, they also presented infected macrophage intensely distributed through the spleen compartments. The failure in parasite growth control may result of a local failure in the pathways of IFNγ expression, especially in disorganized spleen. In fact, cells producing the regulatory cytokines IL4, IFNγ, IL10 and IL17 were detected or more frequently found in the patient with VL and hyperplastic spleen.

In this series, the spleen of the patient VL1 (spleen type 3, disorganized), showed an increased density of CD8+ lymphocyte in the WP not observed in the other patients. This change was not also observed in the studies with dogs [20,28]. Further studies are, therefore, necessary to confirm the relevance of this finding in spleen disorganization in VL.

There was an overall increase of CD68+ macrophage in VL1 patient compared with the patients with VL and organized spleen. Most of the cytokine-producing cell distribution and caspase 3 or Foxp3-expressing cells revealed a trend towards a decrease in density in the WP or RP in the patient with VL and histologic disorganization of the spleen. This finding together with the absence of cells that stained for IL10, IL4, IFNγ, or TGFβ may reflect a state of T cell exhaustion as it has been reported in the spleen of dogs with VL [28].

The spleen of patient VL1 had a unique pattern of gene expression different from that observed in the spleen type 1 of the other two patients. It showed high expression of genes from IL6 signaling pathway (JAK1, JAK2 and PRDM1), and a high density of IL6-producing cells in the RP and the WP, differing from organized spleen, suggesting that this pathway can also be involved in spleen disorganization. IL6 is involved in the induction of inflammatory processes and is found at high levels in plasma of humans and dogs infected with Leishmania infantum [2931]. The IL6 levels have been proposed as a biomarker of prognosis and death in VL [13,32]. One of the outcomes of IL6 signaling is the induction of PRDM1 expression. This gene was found to induce B cell differentiation into plasma cell, to be highly expressed in T cell exhaustion and to induce regulatory FOXP3+ T cell to secrete IL10 [33,34]. T cell exhaustion is a condition that has been associated with the progression of VL and spleen disorganization [28,35,36], particularly in patients with HIV co-infection [4]. The patients with VL of this study showed high expression levels of PRDM1, CD274 (PD-L1), and CD44, which also supports the hypothesis of T cell exhaustion. Conversely, some DEG’s, such as BCL10 and ICOSLG, were highly expressed in type 1 spleen. These genes are associated with co-stimulatory T-cell and B cells proliferation and are involved in B cell differentiation to plasma cells. It is interesting to notice that plasmacytosis establishes since the hyperplastic stage of spleen in VL and remains until the late stage even when the WP is already disrupted [23]. Therefore, these gene expression patterns may correspond to the lymphoid follicle hyperplasia and spleen plasmacytosis observed in some stages of VL. This process of differentiation could be due to TNFα, a cytokine that induce ICOSLG activation and is increased in the type 1—hyperplasic spleen as seen in our patients and in experimental studies [37,38].

Despite patients coinfected VL-HIV having indetectable viral copies in the spleen, changes due to infection may persist and have impact on the outcome of the disease. In fact, there is a percentage of people living with HIV that become immunological non-responders, presenting low CD4 counts even after reduction of viral load [39]. The patients with VL-HIV presented low density splenic CD4+ cells in the WP, low expression of genes such as IL15 and of cytokines related to Th1 response in comparison to the patient with VL monoinfection, also, literature has associated upregulation of genes related to Th2 response and downregulation of IFNG gene before VL treatment in patients VL-HIV coinfected [40]. This observation concurs with previous findings, in which patients with VL-HIV presented more frequent disease relapse, associated to low CD4 counts and low IFNγ in circulating blood [41]. Conversely, IL15 a cytokine associated with induction of Th1 response through IFNγ signaling, contribute to cure in canine VL [42], is upregulated in the patient with VL only. These differences in gene expression patterns and cellular distribution may be distinctive of coinfection status.

The patients with HIV infection (VL1 and VL2) presented extreme changes of the spleen (atrophy and disorganization in patient VL1 and hyperplastic changes inpatient VL3). This may be indicative of dysregulated activation of immune system in LV-HIV infection that may eventually lead to lymphoid tissue disruption and immune system exhaustion. Both conditions VL and HIV infection are both conditions known to be related with WP disruption. On the clinical point of view, these patients also had little improvement of hematological parameters after splenectomy and evolved to death.

The main limitation on this study is the number of subjects. However, to our knowledge, this is the first study combining morphology (conventional and IHC) and transcriptomic analysis and IHC to characterize human spleen changes present in visceral leishmaniasis. The data presented here support the following hypotheses: 1) VL also cause disorganization of spleen compartments in humans. 2) WP disruption is associated to the phenomenon of immune system exhaustion; 3) IL6 may play a role in disorganization and plasma cell accumulation in the spleen.4) low CD4 T cell density and low IL15 expression may contribute to ineffective response to the parasite favoring recurrence of the disease and eventually WP disruption; 5) impaired IFNγ signaling may lead to persistence of Leishmania and chronic inflammation, thereby altering the spleen’s microenvironments and disrupting immune response to infections.

Material and methods

Ethical statement

Written informed consent was obtained from the patients, for publication of this case series as stated in a previously published paper [17].

Clinical and laboratory data

Information was gathered from three adult patients experiencing relapsing VL, showing resistance to standard SbV or amphotericin B treatments, and subsequently undergoing therapeutic splenectomy. Their clinical records were meticulously examined, focusing on key variables: age, gender, disease duration, HIV co-infection, spleen dimensions, fever occurrence, red and white blood cell counts, platelet levels, serum protein levels, as well as any co-infections pre- and post-splenectomy.

Spleen samples

Upon splenectomy, tissue fragments were promptly retrieved from the midsection of the spleen by making a transverse incision across the capsule and the larger axis of the spleen. These fragments were then prepared for histological analysis and gene expression studies in the following manner:

Spleen conventional histology

The collected spleen fragments underwent fixation in formalin-acetic acid-alcohol solution, followed by embedding in paraffin. Tissue sections, 4 micrometers thick, were stained using hematoxylin and eosin, as well as periodic acid–Schiff. Subsequently, two pathologists (WLCS and LARF) conducted examinations, classifying the samples into three categories (spleen type 1, type 2, and type 3) based on the structural organization of the splenic WP. These categories were determined according to established criteria [9,19]: spleen type 1 exhibiting well-organized, reactive WP with distinct peri-arteriolar lymphocyte sheaths and multiple reactive lymphoid follicles characterized by well-defined germinal centers, mantle zones, and marginal zones.; spleen type 2 containing primarily inactive lymphoid follicles, displaying slightly disorganized WP with hyperplastic or hypoplastic changes, resulting in less discernible boundaries between WP compartments.; spleen type 3 Featuring extensively disorganized WP, often presenting poorly discernible compartments, frequent lymphoid atrophy, and a lack of reactive lymphoid follicles.

Cells were morphologically characterized according to previously described criteria: Lymphocytes–cells with round nuclei containing condensed chromatin, inconspicuous nucleoli, and scant cytoplasm. Plasma cells–cells with eccentric nuclei, heterochromatin dispersed around the edge in a pattern like that of the numerals on an analog clock face, and basophilic cytoplasm with clear perinuclear vacuoles. Macrophages–large cells with oval or reniform nuclei containing loosely packed chromatin surrounded by a rim of eosinophilic cytoplasm with indistinct edges. Granulocytes–cells with highly lobulated nuclei containing densely packed chromatin. Megakaryocytes–very large cells with wide and clearly defined cytoplasm and large, lobulated nuclei containing condensed chromatin.

Furthermore, immunohistochemistry was employed for further characterization. Initially, the density of different cell populations within the RP was scored as follows: 0 = no cells, 1 = isolated cells or small aggregates in a small proportion of the examined ×400-magnified microscopic fields, 2 = single cells or aggregates observed in most examined ×400-magnified microscopic fields, and 3 = single cells or aggregates observed in nearly all examined ×400-magnified microscopic fields. These observations were validated through morphometric analysis.

Leukocyte populations and cytokine producing cells

Immunophenotyping and identification of cytokine-producing cells was performed by immunohistochemistry using the following antibodies and procedures: Anti-human molecules antibodies: CD3 (polyclonal produced in rabbit), CD4 (4B12), CD8 (C8/144B), CD20 (L26), CD68 (KP1), CD79α (JCB117), all from Dako (Glostrup, Denmark). Procedures: Deparaffinization and rehydration were performed in xylene, followed by a decreasing series of ethanol solutions and the blockage of endogenous tissue peroxidase in 3% hydrogen peroxide and antigen retrieval was performed using a Dako PT Link (PT100/PT101) high pH module at 97°C for 20 minutes. The DAKO EnVision + HRP kit (Dako Co, Denmark) was used as an amplification system. Diaminobenzidine was used as the chromogen. Sections were counterstained with hematoxylin. Mouse IgG1 isotypes unrelated to the antigens were used as a negative control to replace the primary antibody, except for CD3, that negative control was only incubated with secondary antibody only. Cytokine detection was performed using these primary antibodies: TGFβ (ab66043), IL1β (AF-201-NA), IFNγ (MAB 285), TNFα (AF-210-NA), IL10 (AF-217-NA), IL6 (AF-206-NA), IL17 (AF-317-NA) and IL4 (AF-204-NA) (RD Systems), as well as 14-4776-82 (Foxp3 from E-Bioscience) and Caspase 3, in accordance with the following protocol: Antigen unmasking was performed using a heat-induced antigen retrieval method in a water bath with Retrieval Buffer (Dako Corporation, Carpinteria, CA, USA) for 25 minutes at 95°C, pH 9.0. Next, the sections were incubated in a saponin solution (0.1% in PBS 0.01 M, pH7.4) for 10 minutes at room temperature, followed by incubation in skim milk 10% for 30 minutes and a final incubation with the primary antibodies diluted in 1% bovine albumin–PBS solution, overnight at 4°C. Specific antibody binding was detected using a second antibody and the LSAB system (Dako Corporation, Carpinteria CA, USA, K690) for 30 minutes at 37°C. All reactions were developed using a 3′3 diaminobenzidine chromogen solution and counterstained with Harris hematoxylin. The density of leukocyte cell populations was estimated by morphometry. Since cytokine-producing cells were distributed in small clusters the density of cytokine producing cells was estimated by identifying the two most dense sites of cell clustering and count the cells in this site and in other four non-overlapping areas around this site.

Human spleen transcriptomics

Sample from VL spleen tissue

Total mRNA was initially extracted from tissue fragments using a modified two-step protocol that involved extraction with TRIzol Reagent, followed by further purification using Spin Column-Based technology. Specifically, we macerated tissue fragment samples with 800 μL of TRIzol Reagent (Thermo Fisher Scientific, Cat. no. 15596026) followed by the addition of 160 μL of chloroform (Sigma-Aldrich, Cat. no. 516726), then centrifuged the mixture for 15 minutes at 12,000 x g at 4°C. The obtained aqueous phase was then subjected to additional purification using Spin Column-Based technology (RNeasy Mini Kit 50, Cat. No. / ID: 74104), to ensure the extraction of high-quality total mRNA. The quantity of RNA was measured using NanoDrop (ThermoFischer). The quality of RNA was assessed using Agilent Bioanalyzer automated electrophoresis (Agilent) and considered viable if the RNA integrity number (RIN) was greater than 7. Gene expression analysis was conducted using the nCounter platform by NanoString Technologies, which employs molecular barcodes directly linked to target RNA transcripts, allowing for digital detection. This analysis was performed at the Genomics Core Leuven (VIB/KULeuven—Belgium).

For this assay, two probes were utilized: one to capture specific mRNA through complementary binding and another linked to a fluorescent barcode, aiding in the identification of the target mRNA through hybridization. The combination of these probes with genetic material enables the detection of desired transcripts via fluorescent barcodes.

Sample from healthy spleen tissue

As a control, healthy spleen tissue samples were reanalyzed from the GTEx project [43], which conducted whole-transcriptome profiling of various human tissues, including spleen. Three samples were chosen (S1 Table) based on age and gender similarity to the profile of infected patients. The biomaRt library for R [44] was utilized for gene annotations. Raw reads were mapped against the human genome reference (GRCh38) using STAR [45] with default parameters. HT-seq count [46] assigned and counted mapped reads to annotated genomic features based on GENCODE v. 25 annotations.

Differentially Expressed Genes (DEGs)

Normalization across samples (S1 Fig) was performed multi-step: First, the expression values of all housekeeping genes (S2 Table), s^, were averaged across samples by using the geometric mean. Then, lane scaling factors ci^ were obtained by estimating a combined term as follows: ci^=i=1nsi^n, where i represents each sample. A normalized expression value g^ was estimated for every gene in each sample g by calculating g^=g*ci^. The DEGs data analysis employed an unpaired t-test, assuming individual row variance, and adjusted for False Discovery Rate (FDR) at 1.00% using the two-stage step-up method by Benjamini, Krieger, and Yekutieli.

A heat map (GraphPad Prism Software) was used to display the significant Differentially Expressed Genes (DEGs), illustrating their distribution by converting gene counts into Z-scores. Principal Component Analysis (PCA) was used to reduce the dimensionality of the measured genes in the dataset, effectively capturing the disease conditions of the experiment (Weka 3.9.3, University of Waikato).

Supporting information

S1 Table. GTEx samples used as healthy liver tissue control.

(PDF)

pntd.0011877.s001.pdf (183.1KB, pdf)
S2 Table. Housekeeping genes used during normalization.

(PDF)

pntd.0011877.s002.pdf (111.3KB, pdf)
S3 Table. Differentially Expressed Genes in Normal and VL infected patients.

Each value represents a Log2FC for each gene. ND–Normal Donor; VL–visceral leishmaniasis infected patient.

(XLSX)

pntd.0011877.s003.xlsx (21.4KB, xlsx)
S1 Fig. Genes expression level distribution after normalization.

(PDF)

pntd.0011877.s004.pdf (61.4KB, pdf)
S2 Fig. Heatmap of data from VL patients.

Each row represents each patient (VL1, VL2, VL3), while the number of counts per gene (G), number of cells stained by IHC (C) in WP or RP and laboratorial data (L) are present in columns. The columns were clustered based on Pearson correlation data to each patient. WP- White pulp; RP- Red pulp.

(PDF)

pntd.0011877.s005.pdf (22.9KB, pdf)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq (Financial support grant no. 424776/2016-2 to WLCS; Research productivity scholarship to WLCS; Scholarship "Bolsa Jovem Talentos" to RK) and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES (Financial support to WLCS; PhD scholarship to JLFM; PhD scholarship to CVBM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Saporito L, Giammanco GM, De Grazia S, Colomba C. Visceral leishmaniasis: host–parasite interactions and clinical presentation in the immunocompetent and in the immunocompromised host. International Journal of Infectious Diseases. 2013. Aug;17(8):e572–6. doi: 10.1016/j.ijid.2012.12.024 [DOI] [PubMed] [Google Scholar]
  • 2.Costa CHN, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study. Rev Soc Bras Med Trop. 2010. Aug;43(4):386–92. doi: 10.1590/s0037-86822010000400010 [DOI] [PubMed] [Google Scholar]
  • 3.Cota GF, de Sousa MR, Rabello A. Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review. PLoS Negl Trop Dis. 2011. Jun 7;5(6):e1153. doi: 10.1371/journal.pntd.0001153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Takele Y, Mulaw T, Adem E, Shaw CJ, Franssen SU, Womersley R, et al. Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV. Cell Rep Med. 2022. Jan;3(1):100487. doi: 10.1016/j.xcrm.2021.100487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cota GF, de Sousa MR, de Mendonça ALP, Patrocinio A, Assunção LS, de Faria SR, et al. Leishmania-HIV Co-infection: Clinical Presentation and Outcomes in an Urban Area in Brazil. PLoS Negl Trop Dis. 2014. Apr 17;8(4):e2816. doi: 10.1371/journal.pntd.0002816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lewis SM, Williams A, Eisenbarth SC. Structure and function of the immune system in the spleen. Sci Immunol. 2019. Mar 22;4(33). doi: 10.1126/sciimmunol.aau6085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005. Aug;5(8):606–16. doi: 10.1038/nri1669 [DOI] [PubMed] [Google Scholar]
  • 8.Veress B, Omer A, Satir AA, El Hassan AM. Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology. 1977. Nov;33(5):605–10. [PMC free article] [PubMed] [Google Scholar]
  • 9.Hermida M d. ER, de Melo CVB, Lima IDS, Oliveira GG de S, Dos-Santos WLC. Histological Disorganization of Spleen Compartments and Severe Visceral Leishmaniasis. Front Cell Infect Microbiol. 2018;8(November):394. doi: 10.3389/fcimb.2018.00394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Dutra RA, Dutra LF, Reis M de O, Lambert RC. Splenectomy in a patient with treatment-resistant visceral leishmaniasis: a case report. Rev Soc Bras Med Trop. 2012. Feb;45(1):130–1. doi: 10.1590/s0037-86822012000100027 [DOI] [PubMed] [Google Scholar]
  • 11.Varma N, Naseem S. Hematologic Changes in Visceral Leishmaniasis/Kala Azar. Indian Journal of Hematology and Blood Transfusion. 2010. Sep 30;26(3):78–82. doi: 10.1007/s12288-010-0027-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Costa CHN, Chang KP, Costa DL, Cunha FVM. From Infection to Death: An Overview of the Pathogenesis of Visceral Leishmaniasis. Pathogens. 2023. Jul 24;12(7):969. doi: 10.3390/pathogens12070969 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Costa DL, Rocha RL, Carvalho RMA, Lima-Neto AS, Harhay MO, Costa CHN, et al. Serum cytokines associated with severity and complications of kala-azar. Pathog Glob Health. 2013. Mar 12;107(2):78–87. doi: 10.1179/2047773213Y.0000000078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Montes de Oca M, Engwerda CR, Kaye PM. Cytokines and splenic remodelling during Leishmania donovani infection. Cytokine X. 2020. Dec;2(4):100036. doi: 10.1016/j.cytox.2020.100036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.de Melo CVB, Guimarães Torres F, Hermida MDR, Fontes JLM, Mesquita BR, Brito R, et al. Splenic Transcriptional Responses in Severe Visceral Leishmaniasis: Impaired Leukocyte Chemotaxis and Cell Cycle Arrest. Front Immunol. 2021. Nov 5;12. doi: 10.3389/fimmu.2021.716314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Bagues NCT, Pinheiro CGM de, Bastos LA, Fraga DBM, Veras PST, Pontes-de-Carvalho LC, et al. Parasitic load and histological aspects in different regions of the spleen of dogs with visceral leishmaniasis. Comp Immunol Microbiol Infect Dis [Internet]. 2018;56(July 2017):14–9. Available from: doi: 10.1016/j.cimid.2017.11.003 [DOI] [PubMed] [Google Scholar]
  • 17.Reinaldo LGC, Araújo-Júnior RJC, Diniz TM, Moura RD, Meneses-Filho AJ, Furtado CVVM, et al. Splenectomy in Patients with Visceral Leishmaniasis Resistant to Conventional Therapy and Secondary Prophylaxis: A Retrospective Cohort. Am J Trop Med Hyg. 2022. Aug 17;107(2):342–8. doi: 10.4269/ajtmh.21-0376 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kandasamy K, Mohan S, Raju R, Keerthikumar S, Kumar GSS, Venugopal AK, et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol. 2010;11(1):R3. doi: 10.1186/gb-2010-11-1-r3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Santana CC, Vassallo J, De Freitas LAR, Oliveira GGS, Pontes-De-Carvalho LC, Dos-Santos WLC. Inflammation and structural changes of splenic lymphoid tissue in visceral leishmaniasis: A study on naturally infected dogs. Parasite Immunol. 2008;30(10):515–24. doi: 10.1111/j.1365-3024.2008.01051.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Silva JS, Andrade AC, Santana CC, Santos LQ, de Oliveira CI, Veras PST, et al. Low CXCL13 expression, splenic lymphoid tissue atrophy and germinal center disruption in severe canine visceral leishmaniasis. PLoS One. 2012; doi: 10.1371/journal.pone.0029103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Goto Y, Omachi S, Sanjoba C, Matsumoto Y. Short report: Elevation of serum B-cell activating factor levels during visceral leishmaniasis. American Journal of Tropical Medicine and Hygiene. 2014;91(5):912–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Omachi S, Fujii W, Azuma N, Morimoto A, Sanjoba C, Matsumoto Y, et al. B-cell activating factor deficiency suppresses splenomegaly during Leishmania donovani infection. Biochem Biophys Res Commun [Internet]. 2017;489(4):528–33. Available from: doi: 10.1016/j.bbrc.2017.06.005 [DOI] [PubMed] [Google Scholar]
  • 23.Silva-O’Hare J, De Oliveira IS, Klevorn T, Almeida VA, Oliveira GGS, Atta AM, et al. Disruption of splenic lymphoid tissue and plasmacytosis in canine visceral leishmaniasis: Changes in homing and survival of plasma cells. PLoS One. 2016;11(5):1–17. doi: 10.1371/journal.pone.0156733 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Espitia CM, Saldarriaga OA, Travi BL, Osorio EY, Hernandez A, Band M, et al. Transcriptional profiling of the spleen in progressive visceral leishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes. BMC Immunol. 2014. Dec 26;15(1):38. doi: 10.1186/s12865-014-0038-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kong F, Saldarriaga OA, Spratt H, Osorio EY, Travi BL, Luxon BA, et al. Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease-Promoting Phenotype. PLoS Pathog. 2017. Jan 31;13(1):e1006165. doi: 10.1371/journal.ppat.1006165 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Fakiola M, Singh OP, Syn G, Singh T, Singh B, Chakravarty J, et al. Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. PLoS Negl Trop Dis. 2019. Aug 16;13(8):e0007673. doi: 10.1371/journal.pntd.0007673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.dos-Santos WL, Pagliari C, Santos LG, Almeida VA, e Silva TL, Coutinho J de J, et al. A case of conventional treatment failure in visceral leishmaniasis: leukocyte distribution and cytokine expression in splenic compartments. BMC Infect Dis. 2014. Dec 9;14(1):491. doi: 10.1186/1471-2334-14-491 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.de Souza TL, da Silva AVA, Pereira L de OR, Figueiredo FB, Mendes Junior AAV, Menezes RC, et al. Pro-Cellular Exhaustion Markers are Associated with Splenic Microarchitecture Disorganization and Parasite Load in Dogs with Visceral Leishmaniasis. Sci Rep. 2019. Sep 10;9(1):12962. doi: 10.1038/s41598-019-49344-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Abbehusen MMC, Almeida V dos A, Solcà M da S, Pereira L da S, Costa DJ, Gil-Santana L, et al. Clinical and immunopathological findings during long term follow-up in Leishmania infantum experimentally infected dogs. Sci Rep. 2017. Nov 21;7(1):15914. doi: 10.1038/s41598-017-15651-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Guedes DL, Silva ED da, Castro MCAB, Júnior WLB, Ibarra-Meneses AV, Tsoumanis A, et al. Comparison of serum cytokine levels in symptomatic and asymptomatic HIV-Leishmania coinfected individuals from a Brazilian visceral leishmaniasis endemic area. PLoS Negl Trop Dis. 2022. Jun 17;16(6):e0010542. doi: 10.1371/journal.pntd.0010542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Álvarez L, Marín-García PJ, Rentero-Garrido P, Martinez-Jimenez CP, Llobat L. Interleukin 6 and interferon gamma haplotypes are related to cytokine serum levels in dogs in an endemic Leishmania infantum region. Infect Dis Poverty. 2023. Feb 10;12(1):9. doi: 10.1186/s40249-023-01058-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.dos Santos PL, de Oliveira FA, Santos MLB, Cunha LCS, Lino MTB, de Oliveira MFS, et al. The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14. PLoS Negl Trop Dis. 2016. Jan 27;10(1):e0004375. doi: 10.1371/journal.pntd.0004375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Fu SH, Yeh LT, Chu CC, Yen BLJ, Sytwu HK. New insights into Blimp-1 in T lymphocytes: a divergent regulator of cell destiny and effector function. J Biomed Sci. 2017. Dec 21;24(1):49. doi: 10.1186/s12929-017-0354-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, et al. The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol. 2011. Apr 6;12(4):304–11. doi: 10.1038/ni.2006 [DOI] [PubMed] [Google Scholar]
  • 35.Costa-Madeira JC, Trindade GB, Almeida PHP, Silva JS, Carregaro V. T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis. Front Immunol. 2022. May 2;13. doi: 10.3389/fimmu.2022.835711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Jafarzadeh A, Kumar S, Bodhale N, Jafarzadeh S, Nemati M, Sharifi I, et al. The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden. Cytokine. 2022. May;153:155839. doi: 10.1016/j.cyto.2022.155839 [DOI] [PubMed] [Google Scholar]
  • 37.DE F MICHELIN A, PERRI SH V, DE LIMA VMF. Evaluation of TNF- α, IL-4, and IL-10 and parasite density in spleen and liver of L. (L.) chagasi naturally infected dogs. Ann Trop Med Parasitol. 2011. Jul 22;105(5):373–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Montes de Oca M, Kumar R, de Labastida Rivera F, Amante FH, Sheel M, Faleiro RJ, et al. Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. PLoS Pathog. 2016. Jan 14;12(1):e1005398. doi: 10.1371/journal.ppat.1005398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Bono V, Augello M, Tincati C, Marchetti G. Failure of CD4+ T-cell Recovery upon Virally-Effective cART: an Enduring Gap in the Understanding of HIV+ Immunological non-Responders. New Microbiol. 2022. Jul;45(3):155–72. [PubMed] [Google Scholar]
  • 40.Adriaensen W, Cuypers B, Cordero CF, Mengasha B, Blesson S, Cnops L, et al. Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV. EBioMedicine [Internet]. 2020. May;55:102748. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2352396420301237. doi: 10.1016/j.ebiom.2020.102748 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Takele Y, Mulaw T, Adem E, Womersley R, Kaforou M, Franssen SU, et al. Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load. iScience [Internet]. 2023. Feb;26(2):105867. Available from: https://linkinghub.elsevier.com/retrieve/pii/S258900422202140X. doi: 10.1016/j.isci.2022.105867 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Costa SF, Gomes VO, dos Santos Maciel MO, Melo LM, Venturin GL, Bragato JP, et al. Combined in vitro IL-12 and IL-15 stimulation promotes cellular immune response in dogs with visceral leishmaniasis. Petersen CA, editor. PLoS Negl Trop Dis [Internet]. 2020. Jan 21;14(1):e0008021. Available from: https://dx.plos.org/10.1371/journal.pntd.0008021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013. Jun 29;45(6):580–5. doi: 10.1038/ng.2653 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Smedley D, Haider S, Ballester B, Holland R, London D, Thorisson G, et al. BioMart–biological queries made easy. BMC Genomics. 2009. Dec 14;10(1):22. doi: 10.1186/1471-2164-10-22 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013. Jan 1;29(1):15–21. doi: 10.1093/bioinformatics/bts635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015. Jan 15;31(2):166–9. doi: 10.1093/bioinformatics/btu638 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0011877.r001

Decision Letter 0

Hira L Nakhasi, Abhay R Satoskar

1 Feb 2024

Dear Mr. Fontes,

Thank you very much for submitting your manuscript "Tittle: An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

The study is an important advancement in understanding the dynamics of HIV/VL co infection in real patient samples. Please respond to reviewers comments and concerns especially the interpretation of the data as well as the parameters studied.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Hira L Nakhasi, Ph.D.

Section Editor

PLOS Neglected Tropical Diseases

Abhay Satoskar

Section Editor

PLOS Neglected Tropical Diseases

***********************

The study is an important advancement in understanding the dynamics of HIV/VL co infection in real patient samples. Please respond to reviewers comments and concerns especially the interpretation of the data as well as the parameters studied.

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: (No Response)

Reviewer #2: Methods were well described.

Reviewer #3: The objectives are stated clearly, however, the data are limited and need to be described better to confirm the hypothesis.

The small sample size (3 patients) is adequate for a descriptive clinical study.

Potentially proper statistics are used, they need better description

No concerns about ethics or regulations.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: (No Response)

Reviewer #2: Results are well described.

Reviewer #3: The analysis matches the plan.

The results are extensively presented. However, they are not complete. Gene expression was described as transcripts per gene, yet those numbers were not presented.

The tables are all acceptable. The figures require further explanation.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: The conclusions are largely descriptive consistent with the authors' awareness that the study has few samples. The conclusions drawn often refer to select data to make statements that are not supported by all the data.

The authors focus on stating that the findings in human patients confirm previous results in animals.

The public health benefit is discussed in terms of contribution to the understanding of Leishmania pathogenesis.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: (No Response)

Reviewer #2: (No Response)

Reviewer #3: See attached review memo.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: (No Response)

Reviewer #2: Strength #

1. This study was performed with rare clinical tissue samples, particularly HIV along with Visceral leishmaniasis.

2. Authors used very well acceptable approach to tease out gene expression at mRNA level.

Weakness # 1. As author mentioned in the discussion section about the low number of samples. Nevertheless, still this study will be a good addition for the Leishmania field as there is not much study report regarding HIV-Leishmania co-infection in endemic region.

Overall, study design to analyze the tissue sample and result analysis was well performed. Please see below my comments:

1. Authors have performed cellular distribution analysis with immuno-histochemical analysis. However, as this technique is very challenging and is varies to one antibody marker to another antibody, the Results depicted in Table 3 needs further validation. Cytokine expression level measured from the serum samples of these patient would be an ideal confirmation of these results.

2. IL-6 signaling is driving force for the IL-17 signaling pathway, which further modulates several inflammatory pathways involve in Visceral Leishmaniasis. Please provide the outcome of gene expression analysis of IL-17 pathway.

3. Please provide an access to the Nano string data analysis for the readers or submit the gene expression analysis in public database upon publication of this manuscript.

Reviewer #3: See attached review memo.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Parna Bhattacharya

Reviewer #2: Yes: Ranadhir Dey

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Attachment

Submitted filename: PNTD-D-23-01629.docx

pntd.0011877.s006.docx (13.9KB, docx)
Attachment

Submitted filename: Review of PNTD-D-23-01629.docx

pntd.0011877.s007.docx (40.6KB, docx)
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0011877.r003

Decision Letter 1

Abhay R Satoskar

30 Apr 2024

Dear Dr. dos-Santos,

We are pleased to inform you that your manuscript 'Tittle: An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Abhay R Satoskar

Section Editor

PLOS Neglected Tropical Diseases

Abhay Satoskar

Section Editor

PLOS Neglected Tropical Diseases

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0011877.r004

Acceptance letter

Abhay R Satoskar

9 May 2024

Dear Dr. dos-Santos,

We are delighted to inform you that your manuscript, "Tittle: An integrated analysis of the structural changes and gene expression of spleen in human visceral leishmaniasis with and without HIV coinfection," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. GTEx samples used as healthy liver tissue control.

    (PDF)

    pntd.0011877.s001.pdf (183.1KB, pdf)
    S2 Table. Housekeeping genes used during normalization.

    (PDF)

    pntd.0011877.s002.pdf (111.3KB, pdf)
    S3 Table. Differentially Expressed Genes in Normal and VL infected patients.

    Each value represents a Log2FC for each gene. ND–Normal Donor; VL–visceral leishmaniasis infected patient.

    (XLSX)

    pntd.0011877.s003.xlsx (21.4KB, xlsx)
    S1 Fig. Genes expression level distribution after normalization.

    (PDF)

    pntd.0011877.s004.pdf (61.4KB, pdf)
    S2 Fig. Heatmap of data from VL patients.

    Each row represents each patient (VL1, VL2, VL3), while the number of counts per gene (G), number of cells stained by IHC (C) in WP or RP and laboratorial data (L) are present in columns. The columns were clustered based on Pearson correlation data to each patient. WP- White pulp; RP- Red pulp.

    (PDF)

    pntd.0011877.s005.pdf (22.9KB, pdf)
    Attachment

    Submitted filename: PNTD-D-23-01629.docx

    pntd.0011877.s006.docx (13.9KB, docx)
    Attachment

    Submitted filename: Review of PNTD-D-23-01629.docx

    pntd.0011877.s007.docx (40.6KB, docx)
    Attachment

    Submitted filename: letter review.docx

    pntd.0011877.s008.docx (166KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES